Rigel Pharmaceuticals (RIGL) Non-Current Deffered Revenue (2010 - 2020)
Rigel Pharmaceuticals' quarterly Non-Current Deffered Revenue came in at $146000.0 in Q3 2020, down 99.42% year-on-year from $25.2 million in Q4 2019, and down 90.63% quarter-over-quarter from $1.6 million in Q1 2020.
Rigel Pharmaceuticals has reported Non-Current Deffered Revenue for 11 years, with the latest figure at $146000.0 in Q3 2020.
- For the quarter ending Q3 2020, Non-Current Deffered Revenue fell 99.42% year-over-year to $146000.0; the trailing twelve-month figure through Sep 2020 stood at $146000.0 (down 99.42% YoY), and the FY2019 full-year result was $1.4 million, changed 0.28% from the prior year.
- Non-Current Deffered Revenue for Q3 2020 stood at $146000.0, down from $1.6 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $26.4 million in Q2 2019, with the low at $90000.0 in Q4 2017.
- Average Non-Current Deffered Revenue over 5 years is $6.3 million, with a median of $1.4 million recorded in 2018.
- Year-over-year, Non-Current Deffered Revenue surged 14720.79% in 2019 and slumped 99.42% in 2020.
- Tracing RIGL's Non-Current Deffered Revenue over 5 years: stood at $279000.0 in 2016, then tumbled by 67.74% to $90000.0 in 2017, then soared by 1464.44% to $1.4 million in 2018, then declined by 0.28% to $1.4 million in 2019, then tumbled by 89.6% to $146000.0 in 2020.
- The last three Non-Current Deffered Revenue figures came in at $146000.0 (Q3 2020), $1.6 million (Q1 2020), and $1.4 million (Q4 2019), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 225.10 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Rigel Pharmaceuticals | 551.62 Mn | 404.94 Mn | 54.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 146,000.00 |
| Mar 31, 2020 | 1.56 Mn |
| Dec 31, 2019 | 1.40 Mn |
| Sep 30, 2019 | 25.18 Mn |
| Jun 30, 2019 | 26.40 Mn |
| Mar 31, 2019 | 26.38 Mn |
| Dec 31, 2018 | 1.41 Mn |
| Jun 30, 2018 | 249,000.00 |
| Mar 31, 2018 | 178,000.00 |
| Dec 31, 2017 | 90,000.00 |
| Dec 31, 2016 | 279,000.00 |
| Sep 30, 2016 | 994,000.00 |
| Jun 30, 2016 | 1.71 Mn |
| Mar 31, 2016 | 2.42 Mn |
| Dec 31, 2015 | 3.08 Mn |
| Sep 30, 2015 | 3.66 Mn |
| Jun 30, 2015 | 4.24 Mn |
| Mar 31, 2015 | 4.82 Mn |
| Dec 31, 2014 | 5.35 Mn |
| Sep 30, 2014 | 6.11 Mn |
| Jun 30, 2014 | 6.57 Mn |
| Mar 31, 2014 | 7.03 Mn |
| Dec 31, 2013 | 7.44 Mn |
| Sep 30, 2013 | 7.75 Mn |
| Jun 30, 2013 | 8.07 Mn |
| Mar 31, 2013 | 8.38 Mn |
| Dec 31, 2012 | 8.65 Mn |
| Sep 30, 2012 | 8.83 Mn |
| Jun 30, 2012 | 9.00 Mn |
| Mar 31, 2012 | 9.18 Mn |
| Dec 31, 2011 | 9.31 Mn |
| Sep 30, 2011 | 9.36 Mn |
| Jun 30, 2011 | 9.27 Mn |
| Dec 31, 2010 | 9.06 Mn |